Rib-X Pharma delays IPO after price halved

Rib-X Pharmaceuticals, a New Haven, CT-based developer of antibiotics, opted to delay a planned May 9 initial public offering after chopping the price range of its shares for the maiden stock sale in half to $6 to $7, according to Renaissance Capital. Before postponing the IPO, Rib-X was aiming to raise $65 million in the offering. The biotech, a 2011 Fierce 15 company, is only the latest drug developer to struggle in its efforts to go public. Merrimack Pharmaceuticals ($MACK), also a 2011 Fierce 15 company, delayed an IPO before completing the offering earlier this year. Report

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.